Bioequivalency, Marketing and Protein - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioequivalency

Marketing

Protein

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

FEBRUARY 8, 2021

They include proteins, monoclonal antibodies and vaccines that are considered to be “ highly similar ” to biological products that have already been approved by the FDA. To date, the FDA has approved 29 biosimilars, 19 of which are currently being marketed. What is a Biosimilar?

Production

Production Insulin Branding Generic Drugs

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

FEBRUARY 23, 2023

The sooner challenging and unfixable compounds are identified and killed in development, the less R&D expenditure will be incurred, allowing you to focus on compounds that have the legs to make to it market. However, if drug Y has a high F abs (90%) but low F (e.g. Please check your email to download the Whitepaper.

Development

Development Drugs Bioavailability In-Vivo

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Stay Connected